Stable oral pharmaceutical dosage forms

ABSTRACT

The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

This is a divisional application of prior U.S. patent application Ser.No. 09/141,476 filed Aug. 27, 1998, now U.S. Pat. No. 6,726,927 whichclaims the priority of PCT/US98/09449, filed May 8, 1998, which is acontinuation-in-part of U.S. patent application Ser. No. 08/950,432,filed Oct. 15, 1997, now abandoned, which claims the priority of U.S.Provisional Application No. 60/046,089, filed May 9, 1997, the contentof which are incorporated by reference into this application.

BACKGROUND OF THE INVENTION

U.S. Pat. No. 4,255,431 describes a compound2-[2-(3,5-dimethyl-4-methoxy)-pyridyl methylsulfinyl]-(5-methoxy)-benzimidazole (Omeprazole) or pharmaceuticallyacceptable salt or non-toxic acid addition salt as a therapeuticcompound for mammals including man, suffering from gastric acidsecretion disturbances.

Omeprazole, however is only stable in basic pH conditions and degradesrapidly in neutral or acid pH environment. For this reason theomeprazole oral dosage form must be protected, not only from the acidicinert ingredients used to make a dosage form but also from the acidicgastric fluid in order to intactly reach the absorption site in thesmall intestine.

A study [Drug Dev. Ind. Pharm. 21(8), 965 (1995)] showed the effect ofpH on the stability of omeprazole solution. The pH-decomposition rateprofile curve indicated that the maximum stability was at pH 11. BelowpH 7.8 the decomposition was very fast.

A survey of the stability of Omeprazole products from 13 countries wasreported [Drug Dev. Ind. Pharm. 22(12), 1173(1996)]. The results of thisindependent survey of the stability of omeprazole solid dosage forms (20mg) show that product available in many countries worldwide exhibits avery wide range of stability characteristics. Only 18% of very widerange of stability characteristics. Only 18% of total products tested(34) were considered to demonstrate good physical and chemical stabilityover the course of the study.

U.S. Pat. No. 4,628,098 discloses that: Lansoprazole is a substitutedbenzimidazole2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole, a compound and a pharmacologically acceptable saltthereof that inhibits gastric acid secretion.

Lansoprazole is relatively stable when exposed to light. The compounddegrades in aqueous solution, the rate of degradation increasing withdecreasing pH.

It is well known in the pharmaceutical industry that an enteric coatingtechnology is the most efficient means to protect acid unstablemedication from the attack of the gastric fluid and can rapidly releasethe active drug in the proximal part of the gastrointestinal canal.

An enteric coated dosage form of omeprazole was reported in 1985 byPilbrant and Cederberg (Scand. J. Gastroenterology 1985; 20 (supp.108)p. 113–120). It was found later that the stability of this dosage formwas not sufficient for a long term commercial purpose.

Because of the acidic property of the enteric coating polymer, theomeprazole or lansoprazole will degrade and diminish its therapeuticvalue by direct or indirect contact with it during or after the coatingprocess, even in the presence of alkaline inert ingredients with theactive drug in the core particles. enteric coating as the second layerto release the active drug in the colon.

WO number 85/03436 describes a technique to mix active drug withbuffering components (i.e. sodium dihydrogen phosphate) to maintain aconstant pH in a core for particular purposes. The core is coated with alayer which controls the diffusions.

All of these inventions when applied to omeprazole's or lansoprazole'scase will not give either an adequate release of active drug or storagestability of such dosage form.

U.S. Pat. No. 4,786,505 teaches an art to make an oral pharmaceuticalpreparation comprising (1) a core consisting of omeprazole plus analkaline reacting compound (2) an inert subcoating of core (3) anenteric coating of subcoated core and to use it in the treatment ofgastrointestinal disease.

This technique requires a series of cumbersome and laboriouspharmaceutical processes: 1) preparation of the core, which should besuitable for multilayer coating 2) Coating the core with one or morelayers of an inert subcoating containing one or more alkaline substances3) applying an outer enteric coating to the subcoated core 4) make thepharmaceutical preparation for therapeutical use.

U.S. Pat. No. 5,232,706 claims an oral pharmaceutical preparation ofomeprazole or an alkali salt of omeprazole and a process for producingsuch preparation. The design principle of the preparation is basicallysimilar to the U.S. Pat. No. 4,786,505. This preparation is comprisedof: 1) a nucleus of active drug and first basic organic compound; 2) afirst coating of nucleus containing at least a layer of a basic watersoluble excipient and a second basic organic compound; and 3) a secondcoating formed by an enteric coating.

The major difference between U.S. Pat. No. 5,232,706 and U.S. Pat. No.4,786,505 is the type of basic compound used; the former uses basicorganic compound the later uses inorganic alkaline reaction compounds incore and in subcoating.

U.S. Pat. No. 5,385,739 relates to a stable formulation of Omeprazolemicrogranules containing a neutral core of sugar and starch coated withan active layer of drug and mannitol powder mixture with the aid of asolution of a binding agent in water plus ethanol. An additionalprotective layer of mannitol and sugar syrup is then applied prior tothe final gastroprotection coating.

The art of coating a powder mixture containing an active ingredient ontothe core of sugar and starch by using a binding solution is a ratherdifficult process to obtain uniform drug core granules.

In addition, two applications of aqueous solution involving the directcontact with Omeprazole, in the coating process, may effect thestability of this moisture-sensitive drug.

U.S. Pat. No. 5,399,700 teaches a method for stabilizing an acidunstable benzimidazole derivative, by forming an inclusion complex ofOmeprazole with cyclodextrin.

This inclusion complex was synthesized in an aqueous alkaline solutionat 40°–70° C. and then used to manufacture a tablet which is firstcoated by a water soluble substance and then with an enteric substanceto form an enteric coated oral drug.

The safety of cyclodexrin for human oral dosage form needs to beclarified. Even if the acid stability and dissolution characterizationof this inclusion complex has been well demonstrated in vitro, itsbehavior in vivo is not referenced in this patent.

U.S. Pat. No. 4,689,333 claims a pharmaceutical composition forpreventing or treating digestive ulcers or gastritis which contains aneffective amount of Lansoprazole or a pharmacologically acceptable saltthereof and pharmacologically acceptable carriers.

A study [Drug Dev. Ind. pharm. 18 (13), 1437 (1992)] reported thatenteric granule formulations for Lansoprazole was established, however,it was difficult because some of the excipients needed for theseformulations are incompatible with the drug. The alkaline stabilizerswere then screened and the optimal pH stability of 9 was suggested inthis paper.

A continued study from the above mentioned effort [Drug Dev. Ind. pharm.20(9), 1661 (1994)] attempted to prepare more stable enteric granuleswithout using these troublesome excipients by using a centrifugalfluid-bed granulator instead of an extruder-spheronizer. It was saidthat with this method more stable enteric granules could be obtained.The utilization of special sophisticated equipment to achieve the stablegranules may suffer economical disadvantages.

U.S. Pat. No. 5,026,560 discloses spherical granules having a seed corecoated with a binder and spraying powder containing lansoprazole asactive drug, low substituted hydroxypropylcellulose and magnesium orcalcium carbonate as alkaline agents. The powder coated core is furthercoated with spraying powder of low substituted hydroxypropylcelluloseand then with enteric coating agent.

Technically, powder coating in pharmaceutical manufacturing brings forthissues such as content uniformity of the active on the seed core,laborious process attention and time consumption. It thereforetremendously increases the cost of the product.

U.S. Pat. No. 5,045,321 describes a pharmaceutical composition forcoated tablets or granules, which is comprised of lansoprazole being incontact with at least one of the basic inorganic salts evenly. Noprotective and/or enteric coating is mentioned in the patent claim.

U.S. Pat. No. 5,093,132 is similar to the U.S. Pat. No. 5,045,321 butmore specifically, describes an oral stabilized pharmaceuticalcomposition for the inhibition of gastric acid secretion comprising oflansoprazole or its pharmaceutically acceptable salt in contact evenlywith a basic inorganic salt stabilizing agent. It also mentions simplyan enteric coating for the composition.

Enteric coated oral solid dosage forms have been in existence for acentury. U.S. Pat. Nos. 3,656,997 and 3,959,540 disclosed a coatedgastric juic resistant capsules and process for the production thereof.Most commercially available products under this category are coatedpellets or granule filled capsules and tablet dosage forms. The conceptof an enteric coated capsule dosage for commercial purposes arerelatively new. So far, only one prescription product—VIVOTIF BERNA™(Berna Products, Co., Coral Gables, Fla.) is in the U.S.A. market.

The advantage of enteric coated capsules are duplex. In addition to themerit natures of enteric coating polymers, the problem involved and theneed for extensive efforts in development and the preparation of entericpellets or tablets can be avoided.

Historically, enteric coated hard shell capsules were manufactured withformaldehyde treatments. This technology results in a stability problemwith this product. Since the successful introduction of a number ofenteric polymeric materials, the technology of this coating becomes morepopular and is increasingly used in the pharmaceutical industry.However, the use of organic solvents causes risks of air pollution andinflammability. With the advent and availability of aqueous entericpolymer dispersions, manufacturing of enteric coated dosage forms haveacquired a great deal of attention. The modern coating equipment nowoffers to pharmaceutical manufacturers better conditions for theapplication of aqueous coatings.

The process of enteric coating for pharmaceutical dosage forms are notsignificantly different with other coating processes. Generally, thesample is first placed in the coating pan or in the fluid-bed chamberfor fluidization, while a coating solution is then spraying through agun according to the two operations: 1) spraying or wetting and 2)drying, which is repeated consecutively during the process.

SUMMARY OF THE INVENTION

It is well known that the stability of omeprazole and lansoprazole maybe affected adversely in the presence of water and organic solvent,especially by the former.

The previous art of U.S. Pat. No. 4,786,505 and number 5,232,706 all useconventional aqueous wet technologies to make core pellets orgranulations. This invention, by preferably using dry mixing of drugswith alkaline substances as core granulations for either capsule fillingor direct tablet compression in its processes, can substantiallyeliminate the stability risk of the active by excluding the moisturefrom the core granulation.

The alkaline substances in contact with the enteric coating in theaqueous environment can reduce the acid resistance properties of thelatter. The invention of the above mentioned two U.S. patents includesthe alkaline substances in the subcoating which is directly in contactwith the enteric coating, thus it could be detrimental to the gastricfluid resistance of the enteric coating and result in the inferiortherapeutic efficacy of omeprazole or lansoprazole.

For this reason the present invention uses a capsule shell as aseparating barrier between the alkaline core of active drug and theenteric coatings. In the case of a tablet, only the pure, non-ionicpolymer is used as a protective coating.

Furthermore, the present invention describes an improved oralpharmaceutical dosage form for omeprazole, its salt, lansoprazole or itssalts. It is comprised of 1) a core powder or granules of active drugand alkaline inorganic or organic substances is formed by dry mixing; 2)said powder or granulation is filled into a hard gelatin capsule or isfurther mixed with other pharmaceutical excipients for direct tabletcompression; 3) (for tablet only) a conventional pharmaceuticalprotective coating is disposed on the tablets; and 4) an outer layer ofenteric coating is disposed on the dosage form (capsule or tablet).

This improved dosage form is more economically feasible in terms of timeprocess and material savings. It is sufficiently stable for commercialdistribution and storage. It also effectively protects the active drugfrom the attack of the acidic gastric fluid and efficiently delivers theactive drug to the small intestine.

A process for the manufacturing of an oral dosage form of omeprazole orlansoprazole was also described. The details of granulation,encapsulation, tabletting and coating art can be found in “The Theoryand Practice of Industrial Pharmacy, 1986, Lea & Febiger, Philadelphia,Pa., USA, the content of which is incorporated into this application asa reference.

DETAILED DESCRIPTION OF THE INVENTION

This is an invention of an improved pharmaceutical dosage form for oraladministration to human being or animal host which is comprised of: (a)a core granulation formed by dry mixing an acid-unstable drug or itssalt and an alkaline substance or pharmaceutical excipient without usingan aqueous granulating solution; (b) said dry core granulation can thenbe quantitatively filled into a proper size empty hard gelatin capsuleshell using this shell as a barrier and hence eliminating the process ofapplying a protective coating layer onto the granulation. In otherwords, this hard gelatin capsule shell constitutes simultaneously abarrier between said core granulation and the outer enteric coating ofsaid capsule during the processing to complete the capsule dosage form;and (c) an enteric coating can then be applied onto said capsule toprevent the capsule from releasing the acid-unstable drug in a low pHenvironment (i.e. stomach) and then to deliver the drug in a higher pHenvironment (i.e. small intestine).

As used herein, core granulation is a mixture of a pharmaceuticallyacceptable granulated alkaline substance and, or excipient, and a drugactive ingredient that can be processed into uniform spherelike orregularly shaped aggregates for the improvement of flowability andcompressibility. The manufacturing processes may employ one, or acombination of, four established methods:

-   -   1) dry mixing;    -   2) direct compression;    -   3) milling; and    -   4) non-aqueous granulation.

These methods are described in “The Theory and Practice of IndustrialPharmacy, 1986, Lea & Febiger, Philadelphia, Pa., USA, edited byLachman, L., Lieberman, H. A., and Kanig, J. L.

This invention also includes an improved pharmaceutical dosage form fororal administration to human being or animal host which consists of: (a)a core granulation formed by dry mixing an acid-unstable drug or itssalt, and an alkaline substance or pharmaceutical excipient, withoutusing an aqueous granulating solution, and which can be directlycompressed into a tablet; (b) said tablet can then be filled into anempty, hard gelatin capsule shell using this shell as a barrier andhence eliminating the process of applying a protective layer onto thetablet. In other words, this hard gelatin capsule shell constitutessimultaneously a barrier between the said tablet and an outer entericcoating of said capsule during the processing to complete the capsuledosage form; and (c) an enteric coating can then be applied onto saidcapsule to prevent the capsule from releasing the acid-unstable drug inthe low pH environment (i.e. stomach) and then to deliver the drug in ahigher pH environment (i.e. small intestine).

Also included in this invention is an improved pharmaceutical dosageform for oral administration to human being or animal host whichconsists of: (a) a core granulation formed by dry mixing anacid-unstable drug or its salt, and an alkaline substance orpharmaceutical excipient, without using an aqueous granulating solution,which can then be directly compressed into a tablet; (b) said tablet canthen be coated with a non-ionic protective coating in an orgainc solventas a barrier: (1) to separate the acid-unstable active drug in thetablet from the outer enteric coating and, (2) to protect the outerenteric coating from the permeation of generated alkaline solutionformed by any existed water in the core tablet; and (c) an entericcoating then can be applied onto said tablet to protect it fromreleasing the acid-unstable drug in a low pH environment (i.e. thestomach) and to deliver the active in a higher pH environment (i.e. thesmall intestine).

The protective coating can be applied by a standard film coatingprocedure in a suitable coating machine using a non-aqueous solution.The non-ionic protective polymer is selected from the group consistingof hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropylcellusose, and polyvinylpyrrolidone. The organic solvent is selectedfrom the group consisting of isopropyl alcohol, methanol and ethanol.Other appropriate non-ionic protective polymer may be similarly used.

The plasticizer for protective coating includes, but is not limited to,triethyl citrate, propylene glycol and polyethylene glycol 6000.

In a preferred embodiment, the drug active ingredient comprisesOmeprazole, salt of Omeprazole—selected from the group consisting ofsodium, potassium, calcium and ammonium salts, Lansoprazole or salt ofLansoprazole.

In another embodiment, the alkaline substance of dosage form mentionedabove comprises one or any combination of the following: (a) alkalinemetallic salt of carbonic acid: calcium carbonate, granulated calciumcarbonate; (b) dicalcium phosphate anhydrous, Dibasic sodium phosphateanhydrous, tricalcium phosphate, anhydrous; (c) sodiumcarboxymethylcellulose, calcium carboxymethylcellulose; (d) magnesiumaluminum silicate; (e) sodium lauryl sulfate; (f) sodium bicarbonate;and (g) microcrystalline cellulose, hydroxypropylmethylcellulose,hydroxyethylcellulose.

Also in another embodiment, the pharmaceutical excipient mentioned inthe above dosage forms may be selected from one or any combination ofthe group consisting of dextrose, sorbitol, mannitol, starch, dextrin,maltodextrin, lactose, magnesium stearate, calcium stearate, talc,microcrystalline cellulose, hydroxypropylmethylcellulose andhydroxyethylcellulose.

Also in another embodiment, the pharmaceutical excipient mentioned inthe above dosage forms may be selected from one or any combination ofthe group consisting of dextrose, sorbitol, mannitol, starch, dextrin,maltodextrin, lactose, magnesium stearate, calcium stearate, talc,microcrystalline cellulose, hydroxypropylmethylcellulose andhydroxyethylcellulose. Other appropriate excipients may be similarlyused.

In a separate embodiment, the enteric coating comprises: (a) celluloseacetate phthalate, (C-A-P) cellulose acetate trimellitate (C-A-T),Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), HydroxypropylMethylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP),Anionic phthalate polymers based on methacrylic acid and methacrylicacid esters; (b) compounds either alone or in any combination in organicsolvent, (i.e isopropyl alcohol, methanol, ethanol or ethyl acetate)containing at least one plasticizer (i.e. triethyl citrate, polyethyleneglycol 6000 or glycerol monostearate, as a coating solution; (c) thegroup of compounds in (a) either alone or in any combination in aqueousdispersion containing at least one plasticizer can be an alternativecoating solution; and (d) the process to apply the coating solution ordispersion to said capsules or tablets is a conventional pharmaceuticalmethod. The coating procedures are performed in a suitable coatingmachine.

This invention provides a process for manufacturing the capsule dosageform of above described drug which comprises steps of: (a) preparing thegranulation by preferably dry mixing the active ingredient and alkalinesubstance(s) or by non-aqueous wet granulation method using only thepharmaceutically acceptable organic solvent, preferably methanol,ethanol or isopropyl alcohol as wetting solution and drying thegranulation; (b) filling the capsule with the dried granulation; and (c)coating the capsules with an enteric coating solution or dispersionsolution described above.

This invention provides a aqueous-free process for manufacturing thetablet dosage form that comprises steps of (a) preparing the granulationby preferably dry mixing the active ingredient and alkaline substance orpharmaceutical excipients; (b) directly compressing the granulation intoa tablet by a conventional method; (c) filling the tablet into an emptyhard gelatin capsule shell and; (d) coating the capsule with an entericcoating.

This invention provides an improved pharmaceutical dosage form for oraladministration to human being or animal host containing an acid-unstabledrug active ingredient which comprises: (a) a core tablet formed by drymixing drug or its salt with alkaline substance and pharmaceuticalexcipient or excipients and directly compressing, which can be coatedwith a protective layer as a barrier to: (i) separate the acid-unstableactive drug in the core from the outer enteric coating; and (ii) protectthe entered coating from the permeation of alkaline solution formed bywater in the core tablet; and (b) an enteric coating disposed on saidprotectively coated tablet to protect it from releasing theacid-unstable drug in the stomach and to deliver the active to the smallintestine. In an emobodiment of the above process for manufacturing theimproved pharmaceutical dosage form, the core granulation is prepared bydry mixing, direct tablet compressing, subcoating the tablet withorganic solvent base protective coating; and coating the subcoatedtablets with an enteric coating solution or dispersion.

This invention provides an improved pharmaceutical dosage form for oraladministration to human being or animal host containing an acid-unstabledrug active ingredient which comprises: (a) a core tablet formed by drymixing drug or its salt with alkaline substance and pharmaceuticalexcipient or excipients and directly compressing, which can then becoated with a protective layer as a barrier to: (i)separate theacid-unstable active drug in the core from the outer enteric coating;and (ii) protect the enteric coating from the permeation of alkalinesolution formed by water in the core tablet; (b) an enteric coatingdisposed on said protectively coated tablet to prevent it from releasingthe acid-unstable drug in the stomach and to deliver the active to thesmall intestine; and (c) this tablet is then filled into an empty hardgelatine capsule shell to form a final dosage form. In an embodiment ofthe above process for manufacturing the improved pharmaceutical dosageform, the core granulation is prepared by dry mixing, direct tabletcompressing, subcoating the tablet with organic solvent base protectivecoating, coating the subcoated tablets with an enteric coating solutionor dispersion and filling the said enteric coated tablet into an emptyhard gelatin capsule.

EXAMPLE 1

Core Granulations: Non-Aqueous Wet Granulation:

-   A. Ten grams of omeprazole were granulated with 10 ml. of ethyl    alcohol with agitation. The moist granules were dried and screened    to obtain a uniform granule size.-   B. A suspension of Omeprazole being 10 grams in 50 ml. of ethyl    alcohol was added into 100 grams of an alkaline inert compound being    calcium carbonate granules (DELAVAU, Philadelphia, Pa.) with    agitation to mix homogeneously the liquid and solids. The moist    granules were dried and screened for uniform and adequate granule    size.-   C. Same as Example 1.B., except the alkaline substance is calcium    carbonate 90A (Particle Dynamics, Inc., St. Louis, Mo.)-   D. A mixture of 16 grams of Omeprazole and 10 grams of povidone USP    was dispersed in 15 ml. of ethyl alcohol. The rest of the procedure    is same as Example 1.B. above except that the dispersion was used to    replace the suspension for 84 grams of alkaline substance.-   E. Ten grams of sodium carboxymethylcellulose was dispersed in    10 ml. of ethyl alcohol. This liquid was then used to granulate a    mixture of 2 grams of Omeprazole and 5 grams of calcium carbonate    90A (same as that used in Example 1.C.). The remaining portion of    the procedure is the same as Example 1.B. above.

EXAMPLE 2

Core Granulation: Dry Mixing:

-   A. Ten grams of Omeprazole were mixed with an alkaline substance    being tricalcium phosphate anhydrous USP/NF and then passed through    a screen to obtain a homogenous granule size.-   B. Same Example 2.A. above except the alkaline substance is    pharmaceutical excipient microcrystalline cellulose USP/NF.-   C. Same as Example 2.A. above except the alkaline substance is    pharmaceutical excipient lactose, anhydrous USP.-   D. Same as Example 2.A. above except the alkaline substance is    pharmaceutical excipient maltodextrin.-   E. Same as Example 2.A. above except the alkaline substance is    Calcium Carbonate 90A (same as Example 1.C. above).-   F. Same as Example 2.A. above except the alkaline substance is    Calcium Carbonate granules (same as Example 1.B. above).-   G. Same as Example 2.A. above except the alkaline substance is    Sodium carboxymethylcellulose.

EXAMPLE 3

Encapsulation:

The individual core granulation was mixed with 2% to 5% talc used as alubricant, and then quantitatively encapsulated in hard gelatin capsulesby known pharmaceutical techniques.

EXAMPLE 4

Direct Tablet Compression:

-   A. The individual core granulation was mixed with Lactose and Talc    or magnesium stearate, and compressed into tablets by known    pharmaceutical techniques.

EXAMPLE 5

Capsule Enteric Coating:

The hard gelatine capsules obtained from Example 3. above were entericcoated in a conventional film coating machine with the following coatingsolutions by known pharmaceutical techniques.

Eudragit L-100 ® (Methacrylic Acid Copolymer) 600 Grams IsopropylAlcohol 8,600 Grams Triethyl Citrate 60 Grams FD&C or D&C aluminum laks300 Grams Purified water 400 Grams

EXAMPLE 6

A. Tablet Protective Coating:

The tablets obtained from Example 4. were coated in a conventional filmcoating machine with the following coating solution by knownpharmaceutical techniques.

Methocel E15 ® (Hydroxypropylmethylcellulose) 500 Grams PolyethyleneGlycol E400 110 Grams Ethyl Alcohol 10,000 GramsB. Enteric Coating for Tablets:

The coated tablets obtained from Example 6.A. were enteric coated in aconventional film coating machine with the coating solution being thesame as that used in Example 5. by a known pharmaceutical technique.

EXAMPLE 7

Coated Tablet in a Capsule:

The coated tablets obtained from Example 6.B. were encapsulated in emptyhard gelatin capsules to form a capsule product.

EXAMPLE 8

Several formulations were placed in ambient room temperature conditionsfor stability studies. The color changes of the core granulations wereobserved. Some of the formulations are assayed using USP High PressureLiquid Chromatographic (HPLC) methods to determine the amount of drugremaining. The results are shown on Table 1. below.

TABLE 1 Example Stabliity Omeprazole Time Period Color % of Number(Months) Change Remaining 1.A. 26 + N/A 1.B. 26 0 to + 99.8 1.C. 26 0to + 65.1 1.D. 26 0 to + 96.3 1.E. 11 +++ N/A 2.A. 13 0 89.6 2.B. 13 0N/A 2.C. 11 + 91.0 2.D. 11 ++ 88.2 2.E. +3 11 0 to + 33.6 2.F. +3 11 0to + 97.8 2.G. 11 0 96.2 2.C. +4 11 0 to + N/A 2.F. +3 +5 11 0 to + 96.42.F +6 +7 11 0 to + 95.5 0 = no change + = intensity of color change N/Ano assay was performed

1. A pharmaceutical dosage form for oral administration to human beingor animal host which consists essentially of: (a) a core granulationformed by dry mixing, without using an aqueous granulation solution, anacid-unstable drug with an alkaline substance and a pharmaceuticalexcipient or excipients, wherein the core granulation is capable ofbeing quantitatively filled into an empty hard gelatin capsule shellhaving an outer surface and an inner surface, wherein the hard gelatinecapsule shell separates the core granulation from an enteric coating,and wherein the acid-unstable drug is omeprazole, sodium omeprazole,potassium omeprazole, lansoprazole, or a pharmaceutical salt oflansoprazole; and (b) the enteric coating being disposed on the outersurface of the hard gelatin capsule shell to prevent the release of theacid-unstable drug in the gastric environment and to deliver theacid-unstable drug in the intestinal environment, wherein thepharmaceutical dosage form has more than about 95% of the drug remainingafter 11 months in ambient room temperature conditions.
 2. Apharmaceutical dosage form for oral administration to human being oranimal host which consists essentially of: (a) a core tablet formed bydry mixing, without using an aqueous solution, an acid-unstable drugwith an alkaline substance and a pharmaceutical excipient or excipientsand then by direct compression, wherein the core tablet is capable ofbeing filled into an empty hard gelatin capsule shell having an outersurface and an inner surface, wherein the hard gelatin capsule shellseparates the core tablet from an enteric coating, and wherein theacid-unstable drug is omeprazole, sodium omeprazole, potassiumomeprazole, lansoprazole, or a pharmaceutical salt of lansoprazole; and(b) the enteric coating being disposed on the outer surface of the hardgelatin capsule shell to protect the acid-unstable drug in the gastricenvironment and to deliver the acid-unstable drug in the intestinalenvironment, wherein the pharmaceutical dosage form has more than about95% of the drug remaining after 11 months in ambient room temperatureconditions.
 3. A pharmaceutical dosage form for oral administration tohuman being or animal host which consists essentially of: (a) a coretablet formed by dry mixing, without using an aqueous solution, anacid-unstable drug with an alkaline substance and a pharmaceuticalexcipient or excipients and then by direct compression, wherein theacid-unstable drug is omeprazole, sodium omeprazole, potassiumomeprazole, or a pharmaceutical salt of lansoprazole, and wherein thecore tablet is subcoated with a protective layer as a barrier to: (i)separate the acid-unstable active drug in the core tablet from anenteric coating; and (ii) protect the enteric coating from thepermeation of alkaline solution formed in the core tablet; and (b) theenteric coating being disposed on the protectively subcoated tablet toprotect the coated tablet from releasing the acid-unstable drug in thestomach and to deliver the acid-unstable drug to the small intestine,wherein the pharmaceutical dosage form has more than about 95% of thedrug remaining after 11 months in ambient room temperature conditions.4. The pharmaceutical dosage form according to claim 1, 2 or 3 whereinthe alkaline substance is selected from one or any combination of thegroup consisting of alkaline metallic salt of carbonic acid, calciumcarbonate, granulated calcium carbonate, dicalcium phosphate anhydrous,dibasic sodium phosphate anhydrous, tricalcium phosphate anhydrous,sodium carboxymethylcellulose, calcium carboxymethylcellulose, magnesiumaluminum silicate, sodium lauryl sulfate and sodium bicarbonate.
 5. Thepharmaceutical dosage form according to claim 1, 2 or 3 wherein thepharmaceutical excipient is selected from one or any combination of thegroup consisting of dextrose, sorbitol, mannitol, starch, dextrin,maltodextrin, lactose, magnesium stearate, calcium stearate, talc,microcrystallinecellulose, hydroxypropylmethylcellulose andhydroxyethylcellulose.
 6. The pharmaceutical dosage form according toclaim 1, 2 or 3 wherein the enteric coating comprises: (a) entericpolymer selected from the group consisting of cellulose acetatephthalate, cellulose acetate trimellitate, hydroxypropyl methylcelluloseacetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylacetate phthalate, anionic polymers based on methacrylic acid andmethacrylic acid esters; (b) organic solvent selected from the groupconsisting of isopropyl alcohol, methanol, ethanol and ethyl acetate; tomake polymer solution and aqueous system to make aqueous dispersion ofpolymer; and (c) plasticizer selected from the group consisting oftriethyl citrate, polyethylene glycol 6000 and glycerol monostearate. 7.The pharmaceutical dosage form according to claim 3 wherein theprotective layer comprises: (a) non-ionic protective polymer selectedfrom the group consisting of hydroxypropyl methylcellulose, hydroxyethylcellulose, and hydroxypropyl cellulose polyvinylpyrolidone; (b) organicsolvent selected from the group consisting of isopropyl alcohol,methanol and ethanol; and (c) plasticizer selected from the groupconsisting of triethyl citrate, propylene glycol and polyethylene glycol6000.
 8. An oral pharmaceutical preparation consisting essentially of:(a) a core formulation comprising an acid-unstable drug and an alkalinesubstance, formed by dry mixing without using an aqueous granulatingsolution, wherein the acid-unstable drug is omeprazole, sodiumomeprazole, potassium omeprazole, lansoprazole, or a pharmaceutical saltof lansoprazole; (b) a hard gelatin capsule shell housing the coreformulation, wherein the gelatin capsule shell has an outer surface andan inner surface; and (c) an enteric coating disposed on the outersurface of the hard gelatin capsule, wherein the enteric coating isseparated from the core formulation by the hard gelatin capsule shellwithout a protective coating.
 9. The oral pharmaceutical preparation ofclaim 8, wherein the core formulation further comprises a pharmaceuticalexcipient.
 10. The pharmaceutical dosage form according to claim 9wherein the pharmaceutical excipient is selected from one or anycombination of the group consisting of dextrose, sorbitol, mannitol,starch, dextrin, maltodextrin, lactose, magnesium stearate, calciumstearate, talc, microcrystallinecellulose, hydroxypropylmethylcelluloseand hydroxyethylcellulose.
 11. The oral pharmaceutical preparation ofclaim 8, wherein the core formulation is in the form of powder orgranules.
 12. The oral pharmaceutical preparation of claim 8, whereinthe core formulation is in the form of a tablet.
 13. The pharmaceuticaldosage form according to claim 8 wherein the alkaline substance isselected from one or any combination of the group consisting of alkalinemetallic salt of carbonic acid, calcium carbonate, granulated calciumcarbonate, dicalcium phosphate anhydrous, dibasic sodium phosphateanhydrous, tricalcium phosphate anhydrous, sodiumcarboxymethylcellulose, calcium carboxymethylcellulose, magnesiumaluminum silicate, sodium lauryl sulfate and sodium bicarbonate.
 14. Thepharmaceutical dosage form according to claim 8 wherein the entericcoating comprises: (a) enteric polymer selected from the groupconsisting of cellulose acetate phthalate, cellulose acetatetrimellitate, hydroxypropyl methylcellulose acetate succinate,hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate,anionic polymers based on methacrylic acid and methacrylic acid esters;(b) organic solvent selected from the group consisting of isopropylalcohol, methanol, ethanol and ethyl acetate; to make polymer solutionand aqueous system to make aqueous dispersion of polymer; and (c)plasticizer selected from the group consisting of triethyl citrate,polyethylene glycol 6000 and glycerol monostearate.